Developer docs
API playgroundTry for free, no card

Search company profiles

IN8Bio

Full company profile

uuid0000jkc

Namestring
IN8Bio
Legal namestring
IN8bio, Inc.
Websiteurl
in8bio.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

IN8bio, Inc. (NASDAQ: INAB) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in New York, with research operations in Birmingham, Alabama. The company develops gamma-delta T cell therapies for the treatment of solid and hematological malignancies, and is pursuing adjacent indications in autoimmune disease. Its core technology is the proprietary DeltEx™ platform, which spans four modalities: DeltEx DRI (genetically modified gamma-delta T cells engineered to resist chemotherapy), DeltEx Allo (donor-derived allogeneic cells for leukemia patients undergoing HSCT), DeltEx nsCAR-T (non-signaling CAR constructs that exploit natural gamma-delta T cell killing pathways), and iPSC-derived gamma-delta T cells enabling off-the-shelf products. The clinical pipeline includes INB-400 (Phase 2 newly diagnosed glioblastoma), INB-200 (Phase 1 newly diagnosed glioblastoma), and INB-100 (Phase 1 acute leukemia/HSCT), with preclinical assets INB-300 nsCAR-T, INB-500 iPSC gamma-delta T cells, and INB-619, a gamma-delta T cell engager for autoimmune disease.

IN8bio was the first company to bring genetically modified gamma-delta T cells into the clinic and reports differentiated efficacy signals: 13.0-month median progression-free survival versus 6.6-month standard of care in newly diagnosed GBM, 43% 24-month survival versus 20% for standard-of-care in repeat-dose GBM patients, and 100% complete remission with one-year PFS/OS in INB-100 AML patients (median follow-up 20.1 months), with 30% of those patients surviving beyond three years. The company is led by co-founders William Ho (CEO) and Dr. Lawrence Lamb (CSO), with Kate Rochlin, Ph.D., serving as President and COO, and Patrick McCall as CFO. The board underwent restructuring in February 2026 with Jeremy Graff appointed as Interim Chair.

The business model is pre-commercial: IN8bio generates no product revenue today and will commercialize through FDA-approved cell therapies administered at specialty treatment centers, with future distribution through specialty pharmacy networks. Pricing is undisclosed and will be set upon regulatory approval. The company is funded by equity capital markets rather than operating cash flow, having raised cumulatively more than $130M through a 2019 Series B, a 2022 public offering, and 2023-2025 private placements led by Coastlands Capital. Its go-to-market motion is enterprise/clinical, focused on executing FDA-regulated clinical trials at academic medical centers including O'Neal Comprehensive Cancer Center at UAB, University of Kansas Cancer Center, Ohio State University, and Dana-Farber Cancer Institute.

Short descriptiontext

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid tumors, leukemia, and autoimmune diseases using its proprietary DeltEx™ platform. The company is pre-revenue, with lead programs in Phase 1 and Phase 2 oncology trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gamma-delta T cell therapy, cell therapy oncology, glioblastoma treatment, immunotherapy platform, allogeneic cell therapy
Industry5 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell Therapy / Immuno-oncology Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage company. Revenue will be generated through commercialization of FDA-approved gamma-delta T cell therapies for cancer treatment once clinical trials are successfully completed and regulatory approvals are obtained.

in8bio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1DeltEx
Description

IN8bio's proprietary platform technology for gamma-delta T cell therapies including DeltEx DRI (Drug Resistant Immunotherapy), DeltEx Allo, DeltEx DRI Auto, DeltEx nsCAR-T, and iPSC Gamma-Delta T Cells.

in8bio.com
+2 more records
Core offering1 text field

IN8Bio is a clinical-stage biopharmaceutical company developing a portfolio of gamma-delta T cell therapies for solid tumors, hematologic malignancies, and autoimmune diseases, built on its proprietary DeltEx™ platform that encompasses autologous, allogeneic, iPSC-derived, and genetically modified (DRI, nsCAR) approaches. Lead product candidates include INB-400 (Phase 2 GBM), INB-200 (Phase 1 GBM), and INB-100 (Phase 1 acute leukemia/HSCT), with preclinical INB-300 (nsCAR-T) and INB-619 (T cell engager for autoimmune disease).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 97% improvement in median progression-free survival (13.0 months vs 6.6 months standard-of-care) in newly diagnosed GBM patients
+3 more records
Product overview1 text field

IN8Bio is a clinical-stage biopharmaceutical company developing a portfolio of gamma-delta T cell therapies for cancer and autoimmune diseases. The company's DeltEx™ platform encompasses multiple technology approaches including DeltEx™ DRI (Drug Resistant Immunotherapy), DeltEx™ Allo (allogeneic), DeltEx™ DRI Auto (autologous), DeltEx™ nsCAR-T (non-signaling CAR), and iPSC-derived gamma-delta T cells. The clinical pipeline includes INB-400 (Phase 2, newly diagnosed GBM), INB-200 (Phase 1, newly diagnosed GBM), and INB-100 (Phase 1, acute leukemia/HSCT), while preclinical programs include INB-300/nsCAR-T platform and INB-619 T cell engager for autoimmune diseases. The company was the first to bring genetically modified gamma-delta T cells into the clinic.

Product and service6 records
1INB-200 (DeltEx DRI Auto)
CategoryCell Therapy / Immuno-oncology
Description

Genetically modified autologous gamma-delta T cell product candidate for newly diagnosed glioblastoma (GBM) solid tumors. Engineered to be resistant to alkylating chemotherapy such as temozolomide, enabling concomitant delivery with standard-of-care to maximize tumor killing during chemotherapy-induced stress. The first genetically engineered gamma-delta T cell therapy administered to patients.

2INB-100 (DeltEx Allo)
CategoryCell Therapy / Immuno-oncology
Description

Allogeneic gamma-delta T cell therapy product candidate for patients with acute leukemia undergoing hematopoietic bone marrow transplantation (HSCT). Provides donor-derived allogeneic gamma-delta T cells to patients post-HSCT to maintain remission and prevent relapse, addressing the approximately 50% relapse rate at 12 months post-transplant.

3INB-400 (DeltEx DRI Auto and Allo)
CategoryCell Therapy / Immuno-oncology
Description

Phase 2 product candidate for newly diagnosed glioblastoma (GBM) assessing both autologous and allogeneic genetically modified chemotherapy-resistant gamma-delta T cells. Engineered to be resistant to alkylating chemotherapy so it can be used in combination with the standard-of-care temozolomide (TMZ).

4INB-300 (DeltEx nsCAR-T)
CategoryCell Therapy / Immuno-oncology
Description

DeltEx DRI non-signaling CAR (nsCAR) platform with several preclinical product candidates, including INB-330 targeting CD-33 for AML. The nsCAR constructs lack signaling domains, taking advantage of gamma-delta T cells' natural properties to differentiate between healthy and tumor tissues; the CAR enhances tumor cell targeting while killing only occurs through natural gamma-delta T cell pathways that respond to cellular stress.

5INB-500 (iPSC Gamma-Delta T Cells)
CategoryCell Therapy / Immuno-oncology
Description

iPSC-derived gamma-delta T cell product candidate developed using cell-type specific differentiation processes. IN8bio was the first company to demonstrate the ability to generate both iPSC-derived Vd1+ and Vd2+ gamma-delta T cell subtypes. iPSC-derived gamma-delta cells address donor sourcing and manufacturing expansion limitations, offering potential off-the-shelf therapeutic products.

6INB-619 (Gamma-Delta T Cell Engager)
CategoryCell Therapy / Autoimmune Therapeutics
Description

Next-generation gamma-delta T cell engager (TCE) platform for autoimmune diseases. Preclinical data presented at the 2025 American College of Rheumatology Conference demonstrated deep B cell depletion with a potentially improved safety profile compared to existing autoimmune therapies. IND-enabling studies are progressing with initial animal data expected in 2026.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-05-06
Description

Dr. David Reardon from Dana-Farber Cancer Institute provides clinical perspective on IN8bio's DeltEx DRI therapy program at R&D Day and medical conferences.

2The Ohio State University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-29
Description

Added as a new clinical trial site for INB-100 Phase 1 trial evaluating gamma-delta T cell therapy for leukemia patients undergoing hematopoietic stem cell transplantation. Selected for transplant expertise and operational excellence.

globenewswire.com
3O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site for INB-200 Phase 1 repeat dose escalation trial for newly diagnosed glioblastoma patients.

in8bio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site for INB-100 Phase 1 dose escalation trial for acute leukemia patients undergoing hematopoietic bone marrow transplantation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor developing allogeneic gamma-delta T cell therapies for both oncology and autoimmune disease, overlapping directly with IN8Bio's DeltEx Allo and INB-619 programs. Both companies are pursuing off-the-shelf gamma-delta T cell approaches with significant autoimmune disease focus.

TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered T cell therapies (SPEAR T-cells) for solid tumors. Direct comparable given its focus on cell-based oncology therapeutics and similar clinical-stage profile.

TypeBroad incumbent
Description

Larger, more advanced cell therapy company with FDA-approved TIL therapy (lifileucel) for solid tumors. Comparable in cell therapy approach to solid tumors, with a much later commercial stage that highlights both the opportunity and the gap to bridge for IN8Bio.

TypeDirect peer
Description

Clinical-stage company developing allogeneic CAR-T cell therapies for hematologic malignancies and solid tumors. Highly comparable given the shared allogeneic cell therapy modality and oncology focus.

TypeDirect peer
Description

Clinical-stage company developing iPSC-derived off-the-shelf NK and T cell therapies for cancer and autoimmune disease. Closely comparable to IN8Bio's INB-500 iPSC gamma-delta T cell program in both modality and off-the-shelf positioning.

TypeDirect peer
Description

Clinical-stage company developing iPSC-derived allogeneic cell therapies including gamma-delta T cells and NK cells. Direct comparable given iPSC-derived platform approach and similar early-stage clinical profile.

TypeBroad incumbent
Description

Larger gene-edited cell therapy company with approved CASGEVY for sickle cell disease. Comparable in cell therapy modality and oncology/hematology focus, with significantly greater financial resources and commercial-stage experience.

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic CAR-T cell therapies using CRISPR gene editing. Comparable as a clinical-stage cell therapy peer with similar allogeneic platform positioning.

TypeDirect peer
Description

Clinical-stage company developing gamma-delta T cell therapies for cancer and viral infections. Direct peer in the gamma-delta T cell space, addressing overlapping indications and mechanisms.

TypeDirect peer
Description

Clinical-stage gene-edited allogeneic CAR-T cell therapy company with TALEN-based platform. Comparable in allogeneic cell therapy approach and gene-editing modality, with multiple oncology programs in clinical development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IN8Bio

Cell Therapy / Immuno-oncology Biopharmaceuticalsin8bio.com

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid tumors, leukemia, and autoimmune diseases using its proprietary DeltEx™ platform. The company is pre-revenue, with lead programs in Phase 1 and Phase 2 oncology trials.

What IN8Bio does

IN8bio, Inc. (NASDAQ: INAB) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in New York, with research operations in Birmingham, Alabama. The company develops gamma-delta T cell therapies for the treatment of solid and hematological malignancies, and is pursuing adjacent indications in autoimmune disease. Its core technology is the proprietary DeltEx™ platform, which spans four modalities: DeltEx DRI (genetically modified gamma-delta T cells engineered to resist chemotherapy), DeltEx Allo (donor-derived allogeneic cells for leukemia patients undergoing HSCT), DeltEx nsCAR-T (non-signaling CAR constructs that exploit natural gamma-delta T cell killing pathways), and iPSC-derived gamma-delta T cells enabling off-the-shelf products. The clinical pipeline includes INB-400 (Phase 2 newly diagnosed glioblastoma), INB-200 (Phase 1 newly diagnosed glioblastoma), and INB-100 (Phase 1 acute leukemia/HSCT), with preclinical assets INB-300 nsCAR-T, INB-500 iPSC gamma-delta T cells, and INB-619, a gamma-delta T cell engager for autoimmune disease.

IN8bio was the first company to bring genetically modified gamma-delta T cells into the clinic and reports differentiated efficacy signals: 13.0-month median progression-free survival versus 6.6-month standard of care in newly diagnosed GBM, 43% 24-month survival versus 20% for standard-of-care in repeat-dose GBM patients, and 100% complete remission with one-year PFS/OS in INB-100 AML patients (median follow-up 20.1 months), with 30% of those patients surviving beyond three years. The company is led by co-founders William Ho (CEO) and Dr. Lawrence Lamb (CSO), with Kate Rochlin, Ph.D., serving as President and COO, and Patrick McCall as CFO. The board underwent restructuring in February 2026 with Jeremy Graff appointed as Interim Chair.

The business model is pre-commercial: IN8bio generates no product revenue today and will commercialize through FDA-approved cell therapies administered at specialty treatment centers, with future distribution through specialty pharmacy networks. Pricing is undisclosed and will be set upon regulatory approval. The company is funded by equity capital markets rather than operating cash flow, having raised cumulatively more than $130M through a 2019 Series B, a 2022 public offering, and 2023-2025 private placements led by Coastlands Capital. Its go-to-market motion is enterprise/clinical, focused on executing FDA-regulated clinical trials at academic medical centers including O'Neal Comprehensive Cancer Center at UAB, University of Kansas Cancer Center, Ohio State University, and Dana-Farber Cancer Institute.

IN8Bio firmographics

Firmographics
Name
IN8Bio
Legal name
IN8bio, Inc.
Website
https://in8bio.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid tumors, leukemia, and autoimmune diseases using its proprietary DeltEx™ platform. The company is pre-revenue, with lead programs in Phase 1 and Phase 2 oncology trials.
Ownership category
akta.pro rank

IN8Bio industry classification

Industry
Product category
Cell Therapy / Immuno-oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Gamma-delta T cell therapy
  • Cell therapy oncology
  • Glioblastoma treatment
  • Immunotherapy platform
  • Allogeneic cell therapy

Where IN8Bio is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

IN8Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Revenue will be generated through commercialization of FDA-approved gamma-delta T cell therapies for cancer treatment once clinical trials are successfully completed and regulatory approvals are obtained.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

IN8Bio product offering

Product offering

Core offering

IN8Bio is a clinical-stage biopharmaceutical company developing a portfolio of gamma-delta T cell therapies for solid tumors, hematologic malignancies, and autoimmune diseases, built on its proprietary DeltEx™ platform that encompasses autologous, allogeneic, iPSC-derived, and genetically modified (DRI, nsCAR) approaches. Lead product candidates include INB-400 (Phase 2 GBM), INB-200 (Phase 1 GBM), and INB-100 (Phase 1 acute leukemia/HSCT), with preclinical INB-300 (nsCAR-T) and INB-619 (T cell engager for autoimmune disease).

Product overview

IN8Bio is a clinical-stage biopharmaceutical company developing a portfolio of gamma-delta T cell therapies for cancer and autoimmune diseases. The company's DeltEx™ platform encompasses multiple technology approaches including DeltEx™ DRI (Drug Resistant Immunotherapy), DeltEx™ Allo (allogeneic), DeltEx™ DRI Auto (autologous), DeltEx™ nsCAR-T (non-signaling CAR), and iPSC-derived gamma-delta T cells. The clinical pipeline includes INB-400 (Phase 2, newly diagnosed GBM), INB-200 (Phase 1, newly diagnosed GBM), and INB-100 (Phase 1, acute leukemia/HSCT), while preclinical programs include INB-300/nsCAR-T platform and INB-619 T cell engager for autoimmune diseases. The company was the first to bring genetically modified gamma-delta T cells into the clinic.

Differentiator

Problem solved

Functional benefit

Brands

  • DeltEx: IN8bio's proprietary platform technology for gamma-delta T cell therapies including DeltEx DRI (Drug Resistant Immunotherapy), DeltEx Allo, DeltEx DRI Auto, DeltEx nsCAR-T, and iPSC Gamma-Delta T Cells.
  • DeltEx DRI
  • DeltEx nsCAR-T

Products and services

  • INB-200 (DeltEx DRI Auto) Genetically modified autologous gamma-delta T cell product candidate for newly diagnosed glioblastoma (GBM) solid tumors. Engineered to be resistant to alkylating chemotherapy such as temozolomide, enabling concomitant delivery with standard-of-care to maximize tumor killing during chemotherapy-induced stress. The first genetically engineered gamma-delta T cell therapy administered to patients.
  • INB-100 (DeltEx Allo) Allogeneic gamma-delta T cell therapy product candidate for patients with acute leukemia undergoing hematopoietic bone marrow transplantation (HSCT). Provides donor-derived allogeneic gamma-delta T cells to patients post-HSCT to maintain remission and prevent relapse, addressing the approximately 50% relapse rate at 12 months post-transplant.
  • INB-400 (DeltEx DRI Auto and Allo) Phase 2 product candidate for newly diagnosed glioblastoma (GBM) assessing both autologous and allogeneic genetically modified chemotherapy-resistant gamma-delta T cells. Engineered to be resistant to alkylating chemotherapy so it can be used in combination with the standard-of-care temozolomide (TMZ).
  • INB-300 (DeltEx nsCAR-T) DeltEx DRI non-signaling CAR (nsCAR) platform with several preclinical product candidates, including INB-330 targeting CD-33 for AML. The nsCAR constructs lack signaling domains, taking advantage of gamma-delta T cells' natural properties to differentiate between healthy and tumor tissues; the CAR enhances tumor cell targeting while killing only occurs through natural gamma-delta T cell pathways that respond to cellular stress.
  • INB-500 (iPSC Gamma-Delta T Cells) iPSC-derived gamma-delta T cell product candidate developed using cell-type specific differentiation processes. IN8bio was the first company to demonstrate the ability to generate both iPSC-derived Vd1+ and Vd2+ gamma-delta T cell subtypes. iPSC-derived gamma-delta cells address donor sourcing and manufacturing expansion limitations, offering potential off-the-shelf therapeutic products.
  • INB-619 (Gamma-Delta T Cell Engager) Next-generation gamma-delta T cell engager (TCE) platform for autoimmune diseases. Preclinical data presented at the 2025 American College of Rheumatology Conference demonstrated deep B cell depletion with a potentially improved safety profile compared to existing autoimmune therapies. IND-enabling studies are progressing with initial animal data expected in 2026.

Quantifiable outcome

  • 97% improvement in median progression-free survival (13.0 months vs 6.6 months standard-of-care) in newly diagnosed GBM patients
  • +3 more outcomes

Companies that use IN8Bio

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

IN8Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

IN8Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered supporting and core.

  • Dana-Farber Cancer InstitutesupportingStrategic or Co-development Partner · 6 May 2026Dr. David Reardon from Dana-Farber Cancer Institute provides clinical perspective on IN8bio's DeltEx DRI therapy program at R&D Day and medical conferences.
  • The Ohio State UniversitycoreStrategic or Co-development Partner · 29 October 2025Added as a new clinical trial site for INB-100 Phase 1 trial evaluating gamma-delta T cell therapy for leukemia patients undergoing hematopoietic stem cell transplantation. Selected for transplant expertise and operational excellence.
  • O'Neal Comprehensive Cancer Center at University of Alabama at BirminghamcoreStrategic or Co-development PartnerClinical trial site for INB-200 Phase 1 repeat dose escalation trial for newly diagnosed glioblastoma patients.
  • University of Kansas Cancer CentercoreStrategic or Co-development PartnerClinical trial site for INB-100 Phase 1 dose escalation trial for acute leukemia patients undergoing hematopoietic bone marrow transplantation.

Scale indicators15 records

Recent moves6 records

Expansion highlights5 records

IN8Bio competitors and assessment

Company assessment

Direct peers

  • Adicet Bio: Direct competitor developing allogeneic gamma-delta T cell therapies for both oncology and autoimmune disease, overlapping directly with IN8Bio's DeltEx Allo and INB-619 programs. Both companies are pursuing off-the-shelf gamma-delta T cell approaches with significant autoimmune disease focus.
  • Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered T cell therapies (SPEAR T-cells) for solid tumors. Direct comparable given its focus on cell-based oncology therapeutics and similar clinical-stage profile.
  • Allogene Therapeutics: Clinical-stage company developing allogeneic CAR-T cell therapies for hematologic malignancies and solid tumors. Highly comparable given the shared allogeneic cell therapy modality and oncology focus.
  • Fate Therapeutics: Clinical-stage company developing iPSC-derived off-the-shelf NK and T cell therapies for cancer and autoimmune disease. Closely comparable to IN8Bio's INB-500 iPSC gamma-delta T cell program in both modality and off-the-shelf positioning.
  • Century Therapeutics: Clinical-stage company developing iPSC-derived allogeneic cell therapies including gamma-delta T cells and NK cells. Direct comparable given iPSC-derived platform approach and similar early-stage clinical profile.
  • Caribou Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T cell therapies using CRISPR gene editing. Comparable as a clinical-stage cell therapy peer with similar allogeneic platform positioning.
  • TC BioPharm: Clinical-stage company developing gamma-delta T cell therapies for cancer and viral infections. Direct peer in the gamma-delta T cell space, addressing overlapping indications and mechanisms.
  • Cellectis: Clinical-stage gene-edited allogeneic CAR-T cell therapy company with TALEN-based platform. Comparable in allogeneic cell therapy approach and gene-editing modality, with multiple oncology programs in clinical development.

Broad incumbents

  • Iovance Biotherapeutics: Larger, more advanced cell therapy company with FDA-approved TIL therapy (lifileucel) for solid tumors. Comparable in cell therapy approach to solid tumors, with a much later commercial stage that highlights both the opportunity and the gap to bridge for IN8Bio.
  • CRISPR Therapeutics: Larger gene-edited cell therapy company with approved CASGEVY for sickle cell disease. Comparable in cell therapy modality and oncology/hematology focus, with significantly greater financial resources and commercial-stage experience.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

IN8Bio social profiles

Digital presence

IN8Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IN8Bio leadership team

Management profile

Number of profiles

Profiles6 records

IN8Bio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IN8Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IN8Bio

What does IN8Bio do?

IN8Bio is a clinical-stage biopharmaceutical company developing a portfolio of gamma-delta T cell therapies for solid tumors, hematologic malignancies, and autoimmune diseases, built on its proprietary DeltEx™ platform that encompasses autologous, allogeneic, iPSC-derived, and genetically modified (DRI, nsCAR) approaches. Lead product candidates include INB-400 (Phase 2 GBM), INB-200 (Phase 1 GBM), and INB-100 (Phase 1 acute leukemia/HSCT), with preclinical INB-300 (nsCAR-T) and INB-619 (T cell engager for autoimmune disease).

Is IN8Bio a public or private company?

IN8Bio is a public company. It is classified as public and is currently operating.

When was IN8Bio founded?

IN8Bio was founded in 2016. It employs 11 to 50 people.

Where is IN8Bio based?

IN8Bio is headquartered in New York, United States, in the North America region.

How does IN8Bio make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are IN8Bio's main competitors?

Direct peers on record are Adicet Bio, Adaptimmune Therapeutics, Allogene Therapeutics, Fate Therapeutics, Century Therapeutics, Caribou Biosciences, TC BioPharm and Cellectis. Broad incumbents are Iovance Biotherapeutics and CRISPR Therapeutics.

Does IN8Bio have an API?

No public API is recorded for IN8Bio.

What industry is IN8Bio in?

IN8Bio's product category is Cell Therapy / Immuno-oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingIN8bio Grants New Employee Stock Option to Buy 4,000 SharesIN8bio granted an employee a nonqualified stock option to purchase 4,000 common shares under its 2026 Inducement Plan. The award vests over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, subject to continued employment.Markets DailyIN8bio Highlights Glioblastoma Survival Data, Eyes Autoimmune T-Cell Engager MilestoneIN8bio reported Phase I/II glioblastoma data showing median progression-free survival of 13 months versus 6.6 months for standard care, and overall survival of 19.5 versus 13.2 months. The company plans to present first animal data for its T-cell engager program in fall and expects FDA guidance on a registrational pathway this year.Investing.comEarnings Call Transcripts - Investing.comIN8bio presented its gamma-delta T cell therapy strategy at a Sidoti conference, highlighting in vitro data for its autoimmune program INB-619 and early clinical benefit in glioblastoma. The company raised over $20 million in December 2025 and expects a second close of about $20 million to fund operations through IND submission. Management cited first animal data and FDA guidance as expected catalysts in 2026.Stock TitanIN8bio to Present at Sidoti Conference Sept. 24IN8bio's CEO William Ho will present its γδ T cell platform and pipeline at the Sidoti Small-Cap Virtual Conference on September 24, 2026. The presentation will cover the lead T cell engager program INB-619 and clinical-stage oncology programs, with a live webcast available.AInvestIN8bio at H.C. Wainwright: A Financing Moment, Not a Proof PointIN8bio will present at H.C. Wainwright, but the appearance offers no data or financing updates. The company holds $18M cash and lost $5.1M in Q1 2026, with a going-concern warning. Its gamma-delta T cell therapy showed promising glioblastoma survival data, but financing risk remains.Ticker ReportIN8bio (NASDAQ:INAB) Issues Earnings ResultsIN8bio announced its quarterly earnings results, reporting a loss per share of ($0.25), which exceeded analyst estimates. The company's stock traded slightly higher and was influenced by recent institutional holdings and analyst ratings. IN8bio focuses on developing T cell therapies for unmet medical needs.YahooIN8bio Reports Second Quarter 2026 Financial Results and Recent Business HighlightsIN8bio, Inc reported its second quarter 2026 financial results, highlighting progress in its gamma delta (γδ) T cell therapies and T cell engager platforms for cancer treatment. The company announced clinical milestones, including positive data in glioblastoma trials and advancement of its γδ TCE platform into preclinical studies.Markets DailyIN8bio, Inc. (NASDAQ:INAB) Sees Large Drop in Short InterestIN8bio, Inc. (NASDAQ:INAB) experienced a significant 40.8% drop in short interest during July, with short positions falling from 35,117 shares to 20,789 shares as of July 15th, based on an average trading volume of 53,283 shares. The company's stock traded down 4.9% to $1.03, with a market capitalization of $10.12 million and a consensus analyst rating of "Hold" with a $4.00 price target. Several institutional investors, including HRT Financial LP, Captrust Financial Advisors, and Two Sigma Investments LP, disclosed new stakes in the company during recent quarters.Ticker ReportShort Interest in IN8bio, Inc. (NASDAQ:INAB) Decreases By 40.8%IN8bio, Inc. (NASDAQ:INAB) experienced a 40.8% decline in short interest during July, with short interest falling to 20,789 shares as of July 15th from 35,117 shares at the end of June, based on an average trading volume of 53,283 shares. The company's days-to-cover ratio currently stands at 0.4 days with approximately 0.2% of shares sold short. Research analysts maintain a consensus "Hold" rating with an average price target of $4.00, while institutional investors own approximately 92.05% of the stock.